Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Repeatability of MR Elastography of Liver: A Meta-Analysis.

Serai SD, Obuchowski NA, Venkatesh SK, Sirlin CB, Miller FH, Ashton E, Cole PE, Ehman RL.

Radiology. 2017 Oct;285(1):92-100. doi: 10.1148/radiol.2017161398. Epub 2017 May 22.

PMID:
28530847
2.

Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB).

Liu E, Luthman J, Cedarbaum JM, Schmidt ME, Cole PE, Hendrix J, Carrillo MC, Jones-Davis D, Tarver E, Novak G, De Santi S, Soares HD, Potter WZ, Siemers E, Schwarz AJ.

Alzheimers Dement. 2015 Jul;11(7):840-9. doi: 10.1016/j.jalz.2015.04.001. Review.

PMID:
26194317
3.

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Sep;11(9):1050-68. doi: 10.1016/j.jalz.2014.09.004. Epub 2014 Nov 24. Review.

4.

Robustness of automated hippocampal volumetry across magnetic resonance field strengths and repeat images.

Wolz R, Schwarz AJ, Yu P, Cole PE, Rueckert D, Jack CR Jr, Raunig D, Hill D; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Jul;10(4):430-8.e2. doi: 10.1016/j.jalz.2013.09.014.

PMID:
24985688
5.

Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease.

Hill DL, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, Carrillo MC, Yu P, Sun J, Beckett L, Boccardi M, Brewer J, Brumfield M, Cantillon M, Cole PE, Fox N, Frisoni GB, Jack C, Kelleher T, Luo F, Novak G, Maguire P, Meibach R, Patterson P, Bain L, Sampaio C, Raunig D, Soares H, Suhy J, Wang H, Wolz R, Stephenson D.

Alzheimers Dement. 2014 Jul;10(4):421-9.e3. doi: 10.1016/j.jalz.2013.07.003.

PMID:
24985687
6.

Quantitative imaging biomarkers: a review of statistical methods for technical performance assessment.

Raunig DL, McShane LM, Pennello G, Gatsonis C, Carson PL, Voyvodic JT, Wahl RL, Kurland BF, Schwarz AJ, Gönen M, Zahlmann G, Kondratovich MV, O'Donnell K, Petrick N, Cole PE, Garra B, Sullivan DC; QIBA Technical Performance Working Group.

Stat Methods Med Res. 2015 Feb;24(1):27-67. doi: 10.1177/0962280214537344. Epub 2014 Jun 11. Review.

7.

Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size.

Yu P, Sun J, Wolz R, Stephenson D, Brewer J, Fox NC, Cole PE, Jack CR Jr, Hill DL, Schwarz AJ; Coalition Against Major Diseases and the Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2014 Apr;35(4):808-18. doi: 10.1016/j.neurobiolaging.2013.09.039. Epub 2013 Oct 3.

8.

Standardization of analysis sets for reporting results from ADNI MRI data.

Wyman BT, Harvey DJ, Crawford K, Bernstein MA, Carmichael O, Cole PE, Crane PK, DeCarli C, Fox NC, Gunter JL, Hill D, Killiany RJ, Pachai C, Schwarz AJ, Schuff N, Senjem ML, Suhy J, Thompson PM, Weiner M, Jack CR Jr; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 May;9(3):332-7. doi: 10.1016/j.jalz.2012.06.004. Epub 2012 Oct 27.

9.

Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.

Cole PE, Schwarz AJ, Schmidt ME.

Clin Pharmacol Ther. 2012 Feb;91(2):315-20. doi: 10.1038/clpt.2011.286. Epub 2012 Jan 4. Review.

PMID:
22218072
10.

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

Spira AI, Iannotti NO, Savin MA, Neubauer M, Gabrail NY, Yanagihara RH, Zang EA, Cole PE, Shuster D, Das A.

Clin Lung Cancer. 2012 Jan;13(1):31-8. doi: 10.1016/j.cllc.2011.06.010. Epub 2011 Sep 8.

PMID:
21862415
11.

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease.

Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL.

Alzheimers Dement. 2011 Jul;7(4):474-485.e4. doi: 10.1016/j.jalz.2011.04.007.

12.

Global issues in drug development for Alzheimer's disease.

Doody RS, Cole PE, Miller DS, Siemers E, Black R, Feldman H, Schindler R, Graham S, Heath T, Khachaturian AS, Evans R, Carrillo MC.

Alzheimers Dement. 2011 Mar;7(2):197-207. doi: 10.1016/j.jalz.2011.01.001.

PMID:
21414556
13.

Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities.

Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC, Aerts HJ, Bendriem B, Bendtsen C, Boellaard R, Boone JM, Cole PE, Conklin JJ, Dorfman GS, Douglas PS, Eidsaunet W, Elsinger C, Frank RA, Gatsonis C, Giger ML, Gupta SN, Gustafson D, Hoekstra OS, Jackson EF, Karam L, Kelloff GJ, Kinahan PE, McLennan G, Miller CG, Mozley PD, Muller KE, Patt R, Raunig D, Rosen M, Rupani H, Schwartz LH, Siegel BA, Sorensen AG, Wahl RL, Waterton JC, Wolf W, Zahlmann G, Zimmerman B.

Radiology. 2011 Jun;259(3):875-84. doi: 10.1148/radiol.10100800. Epub 2011 Feb 15.

14.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA.

J Clin Oncol. 2010 Sep 1;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467. Epub 2010 Aug 2.

PMID:
20679609
15.

The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):202-11.e7. doi: 10.1016/j.jalz.2010.03.007. Review.

16.

Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy.

Brown DB, Cardella JF, Sacks D, Goldberg SN, Gervais DA, Rajan DK, Vedantham S, Miller DL, Brountzos EN, Grassi CJ, Towbin RB; SIR Standards of Practice Committee, Angle JF, Balter S, Clark TW, Cole PE, Drescher P, Freeman NJ, Georgia JD, Haskal Z, Hovsepian DM, Kilnani NM, Kundu S, Malloy PC, Martin LG, McGraw JK, Meranze SG, Meyers PM, Millward SF, Murphy K, Neithamer CD Jr, Omary RA, Patel NH, Roberts AC, Schwartzberg MS, Siskin GP, Smouse HR, Swan TL, Thorpe PE, Vesely TM, Wagner LK, Wiechmann BN, Bakal CW, Lewis CA, Nemcek AA Jr, Rholl KS.

J Vasc Interv Radiol. 2009 Jul;20(7 Suppl):S219-S226, S226.e1-10. doi: 10.1016/j.jvir.2009.04.033. No abstract available.

PMID:
19560002
17.

Proof of concept studies for tissue-protective agents in multiple sclerosis.

Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ, Calabresi PA, Cohen JA, Cole PE, Glanzman R, Goelz S, Inglese M, Kapoor R, Kappos L, Kreitman R, Lublin FD, Mann A, Marrie RA, O'Looney P, Polman CH, Ravina BM, Reingold SC, Richert JR, Sandrock AW, Waubant E.

Mult Scler. 2009 May;15(5):542-6. doi: 10.1177/1352458508101939. Review.

PMID:
19389749
18.

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL.

J Clin Oncol. 2009 Jun 20;27(18):2954-61. doi: 10.1200/JCO.2008.17.7618. Epub 2009 Apr 6.

PMID:
19349550
19.

Radiation doses in interventional radiology procedures: the RAD-IR Study. Part III: Dosimetric performance of the interventional fluoroscopy units.

Balter S, Schueler BA, Miller DL, Cole PE, Lu HT, Berenstein A, Albert R, Georgia JD, Noonan PT, Russell EJ, Malisch TW, Vogelzang RL, Geisinger M, Cardella JF, St George J, Miller GL 3rd, Anderson J.

J Vasc Interv Radiol. 2004 Sep;15(9):919-26.

PMID:
15361559
20.

Society of Interventional Radiology position statement on radiation safety.

Cardella JF, Miller DL, Cole PE, Lewis CA; Society of Interventional Radiology.

J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S387. No abstract available.

PMID:
14514852

Supplemental Content

Support Center